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ABSTRACT
Inhibition of androgen receptor (AR) signalling represents the conventional 
medical management of prostate cancer. Ultimately this treatment fails because 
tumors develop an incurable, castrate resistant phenotype, resulting in an unmet need 
for new treatments in prostate cancer. The AR remains a viable therapeutic target 
in castrate resistant disease, such that novel ways of downregulating AR activities 
are attractive as potential treatments. Here we describe a mechanism by which the 
AR can be downregulated by the MDM2 antagonist Nutlin-3, resulting in loss of pro-
survival c-FLIP gene expression and apoptosis. We additionally show that loss of 
c-FLIP sensitises prostate cancer cells to Nutlin-3. Finally, we demonstrate that the 
unrelated MDM2 antagonist Mi-63 also impinges upon AR signalling, supporting the 
concept of future treatment of prostate cancer with MDM2 antagonists.
INTRODUCTION
Numerous lines of evidence implicate the androgen 
receptor (AR) in all stages of prostate cancer, the most 
common male malignancy. Pharmacological inhibition of 
AR activity by androgen deprivation therapy (ADT) is the 
mainstay of treatment in prostate cancer, where curative 
surgery is contraindicated [1]. The major caveat to ADT 
is the development of castrate resistant prostate cancer 
(CRPC), a lethal form of the disease, which emerges after 
long-term administration of anti-androgen compounds 
[2, 3]. Nevertheless, AR activity is retained in CRPC, 
highlighting the concept that alternative means of targeting 
AR could find clinical utility [4-7]. 
Evasion of apoptosis is widely accepted to be 
important in tumorogenesis and chemotherapeutic 
resistance. The pro-survival FLICE-inhibitory protein 
(c-FLIP) is a master regulator of apoptosis that blocks 
activation of the extrinsic (death receptor-mediated) 
apoptotic pathway by inhibiting the formation of the 
death-inducing signalling complex (DISC) and subsequent 
inactivation of PROCASPASE 8 [8]. c-FLIP is aberrantly 
expressed in both high grade prostate cancer and CRPC 
and is a direct target for AR-mediated transcriptional 
activity [9-11]; the c-FLIP gene promoter contains 
defined androgen response elements (AREs). This 
makes c-FLIP the most extensively studied androgen-
responsive pro-survival gene and it has been proposed 
that c-FLIP mediated survival is partly responsible for the 
development of CRPC. A means to block c-FLIP activity 
or expression is therefore potentially beneficial.
p53, the most commonly mutated tumor suppressor 
gene in human cancers, encodes a transcription factor 
responsible for cell cycle arrest and apoptosis in response 
to DNA damage and chemotherapeutic drugs [12]. 
Interestingly, localised prostate tumors contain relatively 
few p53 mutations, whereas metastatic tumors harbor 
far more mutations [13, 14]. This suggests that the less 
aggressive stages of the disease retain functional p53. The 
Mdm2 gene, encoding an E3 ubiquitin ligase enzyme that 
is a key negative regulator of p53, is amplified in around 
7% of all tumors as an alternative means of inactivating 
p53, although this rarely occurs in prostate cancer [15]. 
These observations raise the question of enhancing intact 
p53 activity as a means of treatment in prostate cancer, at 
least in the early stages of disease. Such an approach might 
allow either postponement of traditional anti-androgen 
treatment and the onset of CRPC, or simultaneous / 
cycling administration of p53 activating agents and anti-
androgens, to more effectively eliminate cancerous cells 
whilst they remain vulnerable to both strategies. Intensive 
research into restoring p53 activity in tumors has produced 
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small molecule inhibitors of the p53-MDM2 interaction, 
including the Nutlin compounds and their derivatives, 
some of which are undergoing clinical evaluation [16]. 
Nutlin-3 is the most characterized of these agents and the 
first to be reported as having anti-tumor activity in vivo, 
including inhibition of LNCaP prostate cancer xenograft 
growth [17, 18]. Interestingly, the LNCaP prostate cancer 
cell line, which expresses functional AR exhibited distinct 
apoptotic sensitivity to Nutlin-3, an observation that is 
thus far unexplained. MDM2 gene amplification exists in 
other cell lines that are highly sensitive to Nutlin-3, but 
not in LNCaP cells [18]. AR itself has previously been 
shown to be a target for MDM2-mediated ubiquitination 
and degradation [19, 20]. Although Nutlin-3 disrupts the 
p53-MDM2 interaction, the MDM2 E3 ubiquitin ligase 
activity for non-p53 targets is preserved in the presence of 
Nutlin-3 [21], raising the hitherto unexplored possibility 
that AR could be downregulated by MDM2, in the 
presence of Nutlin-3. This might account for the notable 
sensitivity of LNCaP cells to Nutlin-3. 
Previous work has indeed demonstrated that 
Nutlin-3 treatment reduces AR protein levels and 
produces cell cycle arrest and apoptosis in prostate cancer 
cells expressing active AR and wild-type p53 [22, 23]. 
Additionally, Nutlin-3 also boosts the anti-tumor effect of 
castration in mice [23], however the relative importance 
of Nutlin-3 on AR-mediated survival versus p53-mediated 
cell cycle arrest and apoptosis remains unexplored. Other 
important questions remain around Nutlin-3 activity 
in prostate cancer, including the mechanism of AR 
downregulation, the relative contribution of cell cycle 
arrest versus apoptosis, and the impact upon AR-driven 
pro-survival genes. Moreover, the effects of Nutlin-3 
combined with conventional direct AR antagonists in 
vivo is unclear, as is the question of whether newer anti-
androgens such as enzalutamide (MDV3100) [24], which 
affords increased patient survival in CRPC [25], might 
also be useful in combination with agents such as Nutlin-3.
Here we address some of these questions by 
providing new insight into Nutlin-3 activity in prostate 
cancer cells. We show that sensitivity to Nutlin-3 
treatment correlates with AR dependency in different cells 
models, that otherwise have the same p53 response. This 
suggests that AR signalling is an important determinant 
of Nutlin-3 efficacy, beyond the p53 response, and offers 
an explanation for the marked sensitivity of LNCaP cells 
to Nutlin-3. We go on to show that Nutlin-3 treatment 
increases AR-MDM2 interactions resulting in reduced 
AR levels, loss of AR from the pro-survival c-Flip 
gene promoter, downregulation of c-FLIP expression 
and subsequent downstream cleavage of pro-apoptotic 
CASPASE-8. Consequently, Nutlin-3 combined with 
anti-androgen treatments, or AR depletion, results in 
widespread apoptosis. Conversely, Nutlin-3 combined 
with anti-androgen treatment did not enhance cell cycle 
arrest beyond that observed with Nutlin-3 alone, implying 
that apoptosis is the key mechanism at play. We propose 
that prostate cancers retaining AR and p53 signalling 
might have special significance in the clinical application 
of MDM2 inhibitors in order to prevent or delay the 
development of CRPC, which inevitability emergences 
with the conventional use of anti-androgens. 
RESULTS
AR dependency correlates with sensitivity to 
Nutlin-3 in prostate cancer cell lines
To determine whether any functional link might exist 
between AR signalling and the p53-MDM2 interaction, we 
first examined the sensitivity of 3 related prostate cancer 
cell lines, with differing dependency on AR, to Nutlin-3. 
As shown in Figure 1A, siRNA-mediated depletion of AR 
produced a reduction in proliferation to differing extents 
72 hr post-transfection; low passage number parental 
LNCaP and a casodex-resistant variant LNCaP(CR) 
demonstrated modest, approximately 25% reduction 
in proliferation upon AR silencing. Higher passage 
number cells, LNCaP(hi), however were significantly 
less dependent upon AR for their proliferation, despite 
similar levels of AR knockdown to the other cells, as 
shown by immunoblotting. We next applied increasing 
doses of Nutlin-3 onto the three cell types (Figure 1B) 
in proliferation assays. Whereas the concentration of 
Nutlin-3 required to produce a decrease in proliferation 
by 50% (IC50) was approximately 3μM for both LNCaP 
and LNCaP(CR) cells, the less AR-dependent LNCaP(hi) 
cells exhibited an IC50 of 6μM Nutlin-3. Finally, we treated 
LNCaP cells with the direct AR antagonists enzalutamide 
or casodex in combination with Nutlin-3 for 72 hr (Figure 
1C) before measuring proliferation. Both AR antagonists 
sensitized LNCaP cells to Nutlin-3. Overall, these data 
demonstrate that AR activity correlates with sensitivity to 
Nutlin-3.
To ascertain the mechanism responsible for these 
changes in proliferation, we evaluated cell cycle and 
apoptosis profiles in the LNCaP cells and LNCaP(hi) cells. 
Application of 4-10μM Nutlin-3 to either cell line, for 24 
hr, resulted in a reduction in the number of cells in S-phase 
to similar levels between the cell lines (Figure 2A). 
Additionally, immunoblotting for p53, p21 and MDM2 
demonstrated similar inductions in response to Nutlin-3 
(Figure 2B) demonstrating a conserved p53 response 
between the cell lines. Moreover, silencing AR did not 
lead to an additional reduction in the number of cells in 
S-phase upon treatment with Nutlin-3, in either cell line, 
compared to a non-silencing siRNA (Supplementary 
Figure S1). p53 silencing, on the other hand, increased 
the number of cells in S-phase in the presence of Nutlin-3. 
Overall, we conclude that the differences in proliferation 
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observed between the cell lines upon Nutlin-3 exposure 
cannot be ascribed to cell-cycle control mechanisms and 
the cell cycle arrest exhibited in response to Nutlin-3, 
which is common to both cell lines, is p53-dependent 
rather than AR-dependent.
Upon studying apoptosis in LNCaP cells versus 
LNCaP(hi) cells, we noted a striking difference between 
the cell lines in their response to Nutlin-3 (Figure 2C 
and Supplementary Figure S2). Whereas LNCaP(hi) 
cells exhibited 34.2 % apoptosis in response to 10μM 
Nutlin-3 after 48 hr treatment, LNCaP cells exhibited 
approximately 77.5 % apoptosis. Additionally, siRNA-
mediated AR silencing led to a large increase in the 
apoptotic population in LNCaP cells treated with Nutlin-3, 
compared to a non-silencing control siRNA (Figure 
2D and Supplementary Figure S3). We also observed 
increases in cleaved CASPASE-3 and -8, cleaved PARP 
and p53 in LNCaP cells in response to Nutlin-3, in keeping 
with Nutlin-3 causing apoptosis (Figure 2E). Taking all 
observations together, we conclude that the correlation 
between AR dependency and Nutlin-3 sensitivity observed 
in the proliferation assays is due to changes in apoptosis 
rather than cell cycle arrest, but the p53 response is similar 
between the cells lines.
Nutlin-3 enhances AR-MDM2 interaction, leading 
to AR ubiquitination
In order to understand the mechanism through 
which Nutlin-3 impacts upon AR signalling, we examined 
the AR-MDM2 interaction. LNCaP cells were treated with 
Nutlin-3 for 15-30min prior to AR immunoprecipitation 
Figure 1: Androgen dependency correlates with sensitivity to Nutlin-3. A. Cell lines indicated were reverse transfected in 
96 well plates at a density of 10,000 per well (n = 8) with control or AR siRNA 1 then subject to WST-1 proliferation assay 72 hr later. 
Immunoblotting shows level of AR knockdown between cells lines with two different AR siRNA sequences (C, control siRNA, 1 AR 
siRNA, 2 AR siRNA). B. Indicated cell lines were treated with Nutlin-3 in 96 well plates then subject to WST-1 proliferation assay 72 hr 
later. C. LNCaP cells were treated with combinations of MDV3100 (MDV) or Casodex (CDX) and Nutlin-3 in 96 well plates, then subject 
to WST-1 proliferation assay 72 hr later. Data are representative of a single experiment, error bars ±SD.
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(Figure 3A). This short time period was used so that 
changes in MDM2 levels could not be ascribed as being 
responsible for any change in AR-MDM2 interactions. 
Whilst AR-MDM2 interactions were almost undetectable 
in material from untreated cells, the interaction could be 
readily detected in lysates from cells treated with Nutlin-3, 
without appreciable changes in the total cellular levels of 
MDM2 (Figure 3A). Immunoprecipitation with control 
IgG did not recover significant quantities of either AR 
or MDM2. We additionally tried to examine the p53-
MDM2 complex by co-immunoprecipitation under the 
same conditions. Low basal levels of MDM2, combined 
with dynamic changes in p53 protein levels upon Nutlin-3 
exposure made the results difficult to interpret (data not 
shown), but Nutlin-3 has previously been documented to 
inhibit the p53-MDM2 protein complex. 
The subcellular localisation of AR and MDM2 was 
also examined in response to Nutlin-3 in LNCaP cells 
(Figure 3B). In untreated cells MDM2 did not appear to 
co-localise with AR in either the nucleus or the cytoplasm. 
Conversely, we estimate that more than 50% of AR co-
localised with MDM2 in response to Nutlin-3, which 
was most apparent in the nucleus (Figure 3B and 3C). To 
determine the consequence of this AR-MDM2 interaction, 
we examined the ubiquitination status of AR in response 
to Nutlin-3 using nickel chromatography assays to recover 
His-tagged ubiquitin from transfected 293T cells (Figure 
3D). At shorter exposures to Nutlin-3, such as 15-30min, 
ubiquitination of AR was difficult demonstrate (not 
shown). Additionally, in the absence of Nutlin-3 only 
negligible quantities of ubiquitinated AR were observed. 
However, after 24hr treatment with Nutlin-3 we observed 
an enrichment of high molecular weight AR species, 
presenting as a smear on immunoblotting (Figure 3D). 
Notably, treatment with the proteasome inhibitor MG132 
generated a similar banding pattern, suggesting that 
these species represent ubiquitinated AR. This suggests 
that Nutlin-3 treatment promotes AR ubiquitination. 
Figure 2: Nutlin-3 enhances apoptosis, but not cell cycle arrest, in a manner dependent upon AR status. A. LNCaP 
or LNCaP(hi) cells were treated with Nutlin-3 for 24 hr prior to propidium iodide staining and flow cytometry. Percentages indicate 
proportion of gated cells in S-phase. B. Cells treated as in (A) were subject to immunoblotting with the indicated antibodies. C. Cells were 
treated with Nutlin-3 for 48 hr prior to active caspase-3 staining and analysis by flow cytometry. D. LNCaP cells were transfected with 
control (Ctrl) or AR-targeting siRNAs for 36 hr prior to treatment with Nutlin-3 for 48hr at the doses shown. Cells treated in parallel were 
used for immunoblotting as shown. E. LNCaP cells were treated with Nutlin-3 as indicated prior to immunoblotting as shown. Data are 
representative of a single experiment, error bars ±SD.
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Introduction of a vector carrying a mutant cDNA 
encoding a ubiquitin protein that is incapable of forming 
polyubiquitin chains (K7R), reduced the presence of these 
AR species back to baseline levels, reinforcing the notion 
that these high molecular weight species are indeed (poly)
ubiquitinated AR (Figure 3D). Altogether, we suggest that 
Nutlin-3 treatment promotes AR-MDM2 interactions and 
subsequent AR ubiquitination.
Nutlin-3 treatment reduces the expression of the 
AR-responsive c-FLIP gene
Having demonstrated that exposure to Nutlin-3 
leads to both apoptosis in cells dependent upon AR, 
we questioned what impact Nutlin-3 would have on 
AR-driven pro-survival genes. Previous studies have 
demonstrated that the androgen-responsive pro-survival 
c-FLIP gene is important in prostate cancer [11], making 
it a tractable target to study AR-mediated survival. To 
determine whether Nutlin-3 might influence c-FLIP 
expression, we studied both transcript and protein levels 
Figure 3: MDM2 interacts with AR in response to Nutlin-3 treatment, resulting in AR ubiquitination. A. LNCaP 
cells were treated with 10μM Nutlin-3 prior to immunoprecipitation with either polyclonal AR or IgG control immunoglobulins before 
immunoblotting as indicated. Arrows indicate MDM2 species. B. LNCaP cells were treated with Nutlin-3 prior to dual immunofluorescence 
staining for MDM2 and AR as shown. C. Graph representing percentage of MDM2-AR co-localisation with associated statistical p value 
in table. D. 293T cells were transfected with the plasmids encoding CMV-driven AR, His-tagged ubiquitin or ubiquitin lysine mutant 
K7R prior to treatment with 10μM Nutlin-3 or 5μM MG132 for 24 hr. Purified nickel chromatography and input samples were subject to 
immunoblotting as indicated; AR-ubiquitin smears indicated by bracket. 
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in LNCaP cells exposed to pro-apoptotic concentrations 
of Nutlin-3. After 48hr, exposure of LNCaP cells to 
Nutlin-3 reduced c-FLIP transcript levels by more than 
80% (Figure 4A), and produced a large reduction in both 
detectable c-FLIP isoforms at the protein level (Figure 
4B). Additionally, whilst silencing the AR in LNCaP 
cells led to an expected reduction in c-FLIP expression, 
treatment of these cells with Nutlin-3 produced further 
reductions in c-FLIP expression (Figure 4C and D). 
In order to explain the observed decrease in 
expression of c-FLIP, we examined recruitment of AR to 
the c-FLIP gene by chromatin immunoprecipitation (ChIP) 
in LNCaP cells. Having shown a decrease in AR levels in 
response to Nutlin-3, we postulated that recruitment of AR 
to cis-acting androgen response elements (AREs) might 
also be impaired in this context. Specific oligonucleotides 
were used to amplify a region of the human c-FLIP 
promoter containing 4 characterised AREs upstream 
Figure 4: Nutlin-3 treatment results in loss of AR recruitment to the c-FLIP gene and downregulation of c-FLIP 
expression. A. LNCaP cells were treated with Nutlin-3 for 48 hr prior to analysis of c-FLIP transcript levels, normalised to HPRT 
housekeeping gene expression. B. LNCaP cells treated as in A were subject to immunoblotting as indicated. C. LNCaP cells were 
transfected with the indicated siRNA then treated with Nutlin-3 for 48 hr prior to immunoblotting with indicated antibodies. D. LNCaP 
cells were transfected with the indicated siRNA prior to assessment of c-FLIP or AR transcript levels, as in (A). E. LNCaP cells were treated 
with either 10μM Nutlin-3 or 5μM MDV3100 prior to chromatin immunoprecipitation with either AR or histone H3 tri-methyl lysine 9 
(H3K9Me3) immunoglobulins where shown. Quantities of c-FLIP ARE PCR products are corrected for input samples then expressed as 
fold change over HA immunoglobulin control sample, representative data.
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from the transcription start site. As shown in Figure 4E, 
treatment of cells with the AR antagonist MDV3100 
resulted in a loss of AR recruitment, validating the ChIP 
method as a means to study AR recruitment to the c-FLIP 
gene. Interestingly, treatment with 10µM Nutlin-3 over 24 
hours reduced AR recruitment to the c-FLIP promoter to 
levels detected with a non-specific control HA antibody 
(Figure 4E). An enrichment of the repressive histone H3 
trimethyl lysine 9 (H3K9Me3) mark was also observed, 
further reinforcing the notion that exposure to Nutlin-3 
leads to the formation of an inactive transcriptional state 
upon the c-FLIP gene, and a reduction in c-FLIP levels.
Depletion of c-FLIP sensitises cells to Nutlin-3
We hypothesized that if the decrease in c-FLIP 
levels observed upon Nutlin-3 treatment was in some way 
responsible for apoptosis, then silencing c-FLIP should 
enhance this effect yet further. Firstly, LNCaP cells were 
transfected with siRNA targeting c-FLIP prior to exposure 
to Nutlin-3. Quantitative PCR demonstrated that the 
c-FLIP siRNA was capable of decreasing c-FLIP transcript 
levels by approximately 80% (Supplementary Figure S4). 
Silencing c-FLIP alone led to a marked 50% reduction in 
proliferation compared to non-silencing control siRNA 
(Figure 5A). However, addition of Nutlin-3 even at doses 
as low as 2μM produced more than an 80% decrease in 
proliferation (Figure 5A). 
We then examined apoptosis upon c-FLIP 
knockdown, in combination with Nutlin-3 (Figure 5B 
and Supplementary Figure S5). As expected, Nutlin-3 
exposure led to an increase in the number of apoptotic 
cells, which was enhanced upon silencing AR. Notably, 
silencing c-FLIP sensitized cells to Nutlin-3 with a 
very large increase in apoptotic cell numbers over 
those cells transfected with control siRNA (Figure 
5B). In order to demonstrate that the loss of c-FLIP in 
response to Nutlin-3, AR knockdown, or indeed c-FLIP 
knockdown has an impact on the expected downstream 
pro-apoptotic signalling pathway, we examined levels of 
cleaved CASPASE-3 and -8 in LNCaP cells. Exposure to 
Nutlin-3 led to an increase in the levels of both cleaved 
CASPASE-3 and -8, and this effect was notably enhanced 
upon silencing either AR or c-FLIP (Figure 5B). This data 
suggests that a decreased level of c-FLIP, in response to 
Nutlin-3 is at least partly responsible for the observed 
increase in apoptosis. The fact that AR silencing has a 
similar effect strongly suggests that Nutlin-3 does indeed 
impact on pro-survival AR signalling in human prostate 
cancer cells. 
Finally, to demonstrate that downregulation of AR 
in response to p53-MDM2 inhibition is not specific to the 
Figure 5: c-FLIP knockdown potentiates apoptosis in response to Nutlin-3. A. LNCaP cells were transfected with either control 
(Ctrl) or c-FLIP siRNA (n = 8) then treated with Nutlin-3 for 72 hr prior to WST-1 proliferation assay. B. LNCaP cells were transfected 
with the indicated siRNA prior to treatment with Nutlin-3 for 48 hr as shown. Cells were then subject to flow cytometry measurement of 
Annexin V or immunoblotting, as indicated. C. LNCaP cells were treated with Mi-63 for 36 hr prior to immunoblotting with the indicated 
immunoglobulins.
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Nutlin-3 compound we tested the structurally unrelated 
MDM2 antagonist Mi-63, previously shown to stabilise 
p53 and possess anti-proliferative properties in LNCaP 
cells [29]. Mi-63 treatment produced a dose-dependent 
increase in the expression of the known p53 targets p21 
and MDM2 as expected, but also a reduction in AR protein 
levels. This demonstrates that other MDM2 inhibitors 
impinge upon AR signalling.
DISCUSSION
Novel approaches to targeting AR are worthy of 
investigation and might be of clinical use in the treatment 
of prostate cancers that will otherwise overcome current 
anti-androgen treatments, leading to clinical relapse and 
the emergence of CRPC. Here we describe a mechanism 
by which the AR can be targeted for destruction in 
prostate cancer cells, in a manner that does not directly 
inhibit the AR itself or androgen metabolism, using 
MDM2 antagonists. Other work has demonstrated merit 
in an indirect approach to targeting AR [30], but ours is 
the first study, to our knowledge, showing that AR can 
be successfully down regulated by manipulating its 
natural pathway of destruction, to produce a reduction in 
pro-survival gene expression and consequent increase in 
apoptosis. 
Our data show that the effects of Nutlin-3 on AR 
signalling and apoptosis occur in addition to the previously 
defined p53-mediated effects, and could be responsible 
for the marked sensitivity of LNCaP cells to Nutlin-3. 
Additionally, this sensitivity of LNCaP cells to Nutlin-3 
demonstrates that MDM2 gene amplification is not strictly 
required for the maximal efficacy of MDM2 antagonists. 
This may be clinically relevant, given that prostate cancers 
only rarely harbor MDM2 amplifications. Our data show 
that combined treatment with Nutlin-3 and AR antagonists 
results in widespread apoptosis. This suggests that an in 
vivo assessment of MDM2 antagonists in combination 
with conventional AR antagonists or newer agents such 
as MDV3100 is required, which should result in highly 
effective tumour regression and may delay or prevent the 
onset of castrate resistant disease.
There remain unanswered questions about the 
potential use of MDM2 antagonists in prostate cancer; the 
effects of Nutlin-3 on AR mutants and splice variants that 
arise in aggressive forms of the disease are not yet known 
and the mechanism by which MDM2 inhibitors other than 
Nutlin-3 could destabilise AR are currently unexplored. 
Additionally, the effects of Nutlin-3 and other MDM2 
antagonists have not been thoroughly assessed in prostate 
cancer cell lines that express alternative forms of AR or 
mutant p53, such as VCaP or 22Rv1, although a direct 
comparison between such cells would prove difficult due 
to their rather divergent lineage. Importantly, although 
we suggest that downregulation of c-FLIP is important 
in the response to Nutlin-3 in AR-dependent cells, we 
have not yet obtained a global assessment of other 
androgen-regulated genes in this setting, which might 
shed light on alternative pro-survival mechanisms that 
could be altered in response to Nutlin-3, or explored as 
potential future prostate cancer treatments. Our attempts 
to perform a rescue experiment by transfection of c-FLIP 
prior to treatment with Nutlin-3 generated cytotoxicity 
too prohibitive to determine whether forced expression 
of c-FLIP alone could confer resistance to Nutlin-3. 
Nevertheless, the experiments in which we have inhibited 
AR either by siRNA or anti-androgens suggest that it 
is a target downstream of AR, such as c-FLIP which is 
important in maintaining cell survival and consequent 
disruption of this circuitry confers sensitivity to drug 
treatment.
Despite the above limitations, the majority of 
prostate tumors retain functional AR signalling and 
wild type p53, so we propose that prostate cancer could 
represent an ideal setting in which to make a clinical 
assessment of p53-MDM2 antagonists.
MATERIALS AND METHODS
Cell culture, transfection and immunofluorescence
Parental LNCaP cells were extensively cultured to 
> 50 passages to obtain high passage LNCaP(hi) cells. 
Casodex resistant LNCaP(CR) cells have been previously 
described [26]. Proliferation assays were performed using 
WST-1 reagent (Invitrogen) as described [22]. siRNA 
transfection was performed with RNAiMAX as per 
manufacturers recommendations with a final concentration 
of 25nM siRNA. For Immunofluorescence, cells were 
cultured for 72h on coverslips prior to treatment with 
either DMSO, 10-20µM Nutlin for 30 min. Cells were 
fixed with ice cold methanol, stained and imaged using 
Zeiss LSM 700 confocal microscope. Co-localisation 
of proteins was analysed using Zen2009 software to 
quantify average co-localisation of AR and MDM-2. All 
experiments have been performed 3 times.
Flow cytometry
Cell cycle profiles were obtained at 24hr exposure to 
Nutlin-3, whilst cells remained viable, by permeablising in 
1% Triton-X-100 in PBS followed by treatment with 100 
µg/ml RNase and 500 µg/ml propidium iodide for 10 min. 
Cells were then washed in PBS prior to analysis.
Apoptosis was measured using either active 
caspase-3 (BD Pharmingen, cat 550480) or Annexin V / 
propidium iodide staining (BD Pharmingen, cat 556547) 
as described by manufacturer. No cells were gated out of 
analysis. In the case of caspase-3 a discrete population 
was observed and quantitated respective to the unstained 
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population (see Figure S2). For Annexin V, all positively 
stained cells were counted (see Figure S3).
Antibodies, reagents and oligonucleotides
Antibodies included MDM2 (Santa Cruz), p53 and 
p21 (Cell signalling technologies), AR (BD Biosciences), 
Caspase-3, 8 and PARP as described [27]. Nutlin-3, 
MG132 and siRNA were obtained from Sigma.
Nickel chromatography, immunoprecipitation 
and chromatin immunoprecipitation
Ni-NTA agarose (Qiagen) was used to purify 
His-tagged ubiquitin modified proteins under 
reducing conditions as previously described [19]. 
Immunoprecipitation was performed after lysis in 50 
mM Tris HCl, pH 7.4, with 150 mM NaCl, 1 mM EDTA, 
and 1% TRITON-X-100, supplemented with cOmplete 
protease inhibitors (Roche), using 1μg of AR or control 
immunoglobulin (Dako) bound to Protein G Sepharose 
(GE healthcare). Chromatin immunoprecipition was 
performed as described [28] and oligonucleotides 
sequences were used to amplify c-FLIP AREs; 5’ 
CGACGAGTCTCAACTAAAAGGGA 3’ and 5’ 
CGCTTCTCTCCTACACCTCCTC 3’.
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